Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
    Meeting Abstract

    Kyi, C. K.; Spira, A.; Carbone, D. P.; Johnson, M. L.; Henick, B. S.; Johnson, B.; Borghaei, H.; Mahipal, A.; Hecht, J. R.; Catenacci, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results
    Meeting Abstract

    Gutierrez, M.; Friedman, C. F.; Long, G. V.; Ascierto, P. A.; Melero, I.; Richards, D.; Bastos, B. R.; Moreno Garcia, V.; Uemura, M.; Conkling, P.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL
    Meeting Abstract

    Matasar, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Meeting Abstract

    Hong, D. S.; Tahara, M.; Baik, C.; Bauman, J. R.; Gilbert, J.; Brose, M. S.; Grilley-Olson, J. E.; Patil, T.; McDermott, R.; Raez, L. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, L. S.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
    Meeting Abstract

    Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study
    Meeting Abstract

    Colombo, N.; Van Gorp, T.; Matulonis, U. A.; Oaknin, A.; Grisham, R. N.; Fleming, G.; Olawaiye, A.; Tudor, I. C.; Pashova, H. I.; Lorusso, D.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial
    Meeting Abstract

    Friedman, C. F.; D'Souza, A. A.; Tinker, A. V.; Corral, E.; Gambardella, V.; Goldman, J. W.; Loi, S.; Melisko, M.; Oaknin, A.; Spanggaard, I.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor a (FR a)-positive cancer
    Meeting Abstract

    Matulonis, U. A.; Moore, K. N.; Lorusso, D.; Oaknin, A.; Pignata, S.; Denys, H.; Colombo, N.; Van Gorp, T.; Konner, J.; Romeo Marin, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor a (FRa)-positive cancer
    Meeting Abstract

    Moore, K. N.; Lorusso, D.; Oaknin, A.; Pignata, S.; Denys, H.; Colombo, N.; Van Gorp, T.; Konner, J.; Romeo Marin, M.; Harter, P.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save